Prostate cancer Board decisions

The Board denied higher ratings for diabetes mellitus and peripheral neuropathy, granted a 20% rating for left and right lower extremity peripheral neuropathy of the sciatic nerve, and granted a TDIU from April 21, 2021.

The Board dismissed the appeals for service connection for hearing loss, malignant growths of the genitourinary system (prostate cancer), and Parkinson's disease due to improper election of review options. The claim for sleep apnea was remanded for further development.

The Board remands the Veteran's claim for a compensable rating for residuals of prostate cancer, status post RALP, to obtain an adequate medical examination.

The Board granted service connection for prostate cancer, finding a nexus to toxic exposures in service at Camp Lejeune.

The Board granted a 100 percent rating for prostate cancer status post radical prostatectomy from April 27, 2023 to February 24, 2025, but dismissed the appeal as moot beginning February 25, 2025.

The Board remands the claim for service connection for prostate cancer to obtain an addendum medical opinion regarding its etiology, including jet fuel exposure.

The Board granted service connection for prostate cancer, resolving reasonable doubt in the Veteran's favor based on evidence of in-service exposure to carcinogens.

The Board granted a 100 percent rating for prostate cancer status post radical prostatectomy from April 27, 2023 to February 24, 2025, but dismissed the appeal as moot beginning February 25, 2025.

The Board dismissed the claim for service connection for prostate cancer and denied an earlier effective date for urinary incontinence residuals of adenocarcinoma of the prostate (s/p prostatectomy).

The Board granted service connection for residuals of prostate cancer, to include urinary incontinence, based on the Veteran's exposure to ionizing radiation during active service.

The Board remands the claims for service connection for prostate cancer and skin cancer due to ionizing radiation exposure, as a VA examination is needed to determine their likely etiology.

The Board granted service connection for diabetes mellitus type II, hepatitis B, a liver condition (hepatic steatosis and cirrhosis) secondary to service-connected hepatitis B, hypertension, prostate cancer, voiding dysfunction as secondary to service-connected prostate cancer, and erectile dysfunction as secondary to service-connected prostate cancer. The claim for anemia was remanded.

The Board denied service connection for prostate cancer, major depressive disorder, sleep apnea, headaches, substance abuse, and chronic pain syndrome as the evidence did not support a finding that these conditions were incurred in or aggravated by the Veteran's active service, including exposure to contaminated water at Camp Lejeune.

The Board remanded the Veteran's claim for compensation under 38 U.S.C. § 1151 for residuals of prostate cancer due to inadequate VA medical opinions. A new VA medical examination and opinion is required to determine whether VA's failure to timely diagnose and treat the Veteran's prostate cancer proximately caused the additional disability.

The Board denied service connection for malaria and prostate cancer, while remanding claims for a kidney disorder, sinusitis, respiratory disorders, eye/vision disorder, generalized anxiety disorder, and acquired psychiatric disorder.

The Veteran's service-connected voiding dysfunction, alone, precludes him from earning substantially gainful income from employment, and he is granted a total disability rating based on individual unemployability (TDIU) beginning July 28, 2021, along with special monthly compensation for statutory housebound status.

The Board denied entitlement to a total disability rating based on individual unemployability (TDIU), on an extra-schedular basis, prior to July 23, 2019.

The Board granted service connection for prostate cancer and hypertension based on the evidence showing in-service exposures to non-tactical herbicides, which are linked to these conditions.

The Board remands the claims for service connection for sleep apnea, prostate cancer, and diabetes mellitus type II due to an incomplete review of potential Agent Orange exposure during the Veteran's service in Korea.

The Board granted service connection for prostate cancer, resolving reasonable doubt in favor of the Veteran.